BR112013030973A2 - processo para a preparação de amidas de prostaglandina - Google Patents

processo para a preparação de amidas de prostaglandina

Info

Publication number
BR112013030973A2
BR112013030973A2 BR112013030973A BR112013030973A BR112013030973A2 BR 112013030973 A2 BR112013030973 A2 BR 112013030973A2 BR 112013030973 A BR112013030973 A BR 112013030973A BR 112013030973 A BR112013030973 A BR 112013030973A BR 112013030973 A2 BR112013030973 A2 BR 112013030973A2
Authority
BR
Brazil
Prior art keywords
group
formula
atom
general formula
meanings
Prior art date
Application number
BR112013030973A
Other languages
English (en)
Other versions
BR112013030973B1 (pt
BR112013030973A8 (pt
Inventor
Gábor Havasi
Irén Hortobágyi
István Lászlófi
Tibor Kiss
Zoltán Bischof
Zsuzsanna Kardos
Original Assignee
Chinoin Gyógyster És Vegyészeti Termékek Gyára Zrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU1100292A external-priority patent/HU231134B1/hu
Priority claimed from HU1100291A external-priority patent/HU230703B1/hu
Application filed by Chinoin Gyógyster És Vegyészeti Termékek Gyára Zrt filed Critical Chinoin Gyógyster És Vegyészeti Termékek Gyára Zrt
Priority to BR122021008946-9A priority Critical patent/BR122021008946B1/pt
Priority to BR122021008918-3A priority patent/BR122021008918B1/pt
Publication of BR112013030973A2 publication Critical patent/BR112013030973A2/pt
Publication of BR112013030973A8 publication Critical patent/BR112013030973A8/pt
Publication of BR112013030973B1 publication Critical patent/BR112013030973B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/50Iso-indoles; Hydrogenated iso-indoles with oxygen and nitrogen atoms in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

resumo patente de invenção: "processo para a preparação de amidas de prostaglandina". a presente invenção refere-se a um processo para a preparação de amidas de prostaglandina da fórmula geral (i), em que na fórmula, as ligações marcadas com linhas pontilhadas podem ser ligações simples ou duplas, no caso de ligações duplas nas posições 5,6 e 13,14, essas podem estar na orientação cis ou trans, q representa um grupo hidroxila e z representa um grupo hidroxila ou oxo, r1 e r2 independentemente, representam um átomo de hidrogênio ou um grupo c1-10-alquila ou aralquila em cadeia linear ou ramificada, opcionalmente substituído com um grupo -ono2 ou um grupo aralquila ou arila, que contém heteroátomo, r3 representa um grupo c4-6 hidrocarboneto saturado ou insaturado, em cadeia linear ou ramificada ou um grupo c4-10 alquilcicloalquila ou cicloalquila ou um grupo fenila, c7-10 alquilarila ou hetarila opcionalmente substituído com um grupo alquila ou com um átomo de halogênio, y representa um grupo (ch2)n ou um átomo de o ou átomo de s e em que n=0-3, caracterizado pelo fato de que um ácido de fórmula geral (ii), em que na fórmula as ligações marcadas com linhas pontilhadas podem ser ligações simples ou duplas, no caso de ligações duplas nas posições 5,6 e 13,14, essas podem estar na orientação cis ou trans, q representa um grupo hidroxila e z representa um grupo hidroxila ou oxo, r3 representa um grupo c4-6 hidrocarboneto saturado ou insaturado, em cadeia linear ou ramificada ou um grupo c4-10 alquilcicloalquila ou cicloalquila ou um grupo fenila, c7-10 alquilarila ou hetarila opcionalmente substituído com um grupo alquila ou com um átomo de halogênio, y representa um grupo (ch2)n ou um átomo de o ou átomo de s e em que n=0-3, é reagido i) com um composto adequado para introduzir o grupo r4, em que r4 representa a.) o grupo da fórmula a.) e a amida resultante da fórmula geral (iii), em que os significados de r3, r4, y e n são como definidos acima, é reagida com uma amina da fórmula geral (iv), nhr1r2 iv. em que os significados de r1 e r2 são definidos acima ou ii) com um composto adequado para introduzir o grupo r5 - em que r5 representa um grupo da fórmula b.), c.), d.) ou e.), em que (x) representa um átomo de halogênio ou um átomo de hidrogênio e o éster ativado resultante da fórmula geral (v), em que os significados de r3, r5, y e n são como definidos acima, é reagido com uma amina da fórmula geral (iv) ou iii.) com uma amina da fórmula geral (iv) - em que os significados de r1 e r2 são como definidos acima - na presença de cloreto de 2-cloro-1,3-dimetilimidazolínio e uma base. outra concretização da nossa invenção é um processo para a preparação de uma forma cristalina de ponto de fusão elevado de bimatoprosta da fórmula (ib). outra concretização da invenção é um processo para a preparação de um composto da fórmula (iib) em forma cristalina.
BR112013030973-3A 2011-06-02 2012-05-25 Processo para a preparação de amidas de prostaglandina BR112013030973B1 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR122021008946-9A BR122021008946B1 (pt) 2011-06-02 2012-05-25 Composto em sua forma cristalina e processo para a preparação do mesmo
BR122021008918-3A BR122021008918B1 (pt) 2011-06-02 2012-05-25 Forma cristalina ii de bimatoproposta e processo para a preparação da mesma

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
HU1100292A HU231134B1 (hu) 2011-06-02 2011-06-02 Eljárás a bimatoprost kémiailag stabil új kristályformájának előállítására
HU1100291A HU230703B1 (hu) 2011-06-02 2011-06-02 Új eljárás prosztaglandin amidok előállítására
HUP1100291 2011-06-02
HUP1100292 2011-06-02
PCT/HU2012/000045 WO2012164324A1 (en) 2011-06-02 2012-05-25 Novel processes for the preparation of prostaglandin amides

Publications (3)

Publication Number Publication Date
BR112013030973A2 true BR112013030973A2 (pt) 2016-08-16
BR112013030973A8 BR112013030973A8 (pt) 2021-03-30
BR112013030973B1 BR112013030973B1 (pt) 2021-08-10

Family

ID=89990312

Family Applications (3)

Application Number Title Priority Date Filing Date
BR122021008918-3A BR122021008918B1 (pt) 2011-06-02 2012-05-25 Forma cristalina ii de bimatoproposta e processo para a preparação da mesma
BR122021008946-9A BR122021008946B1 (pt) 2011-06-02 2012-05-25 Composto em sua forma cristalina e processo para a preparação do mesmo
BR112013030973-3A BR112013030973B1 (pt) 2011-06-02 2012-05-25 Processo para a preparação de amidas de prostaglandina

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR122021008918-3A BR122021008918B1 (pt) 2011-06-02 2012-05-25 Forma cristalina ii de bimatoproposta e processo para a preparação da mesma
BR122021008946-9A BR122021008946B1 (pt) 2011-06-02 2012-05-25 Composto em sua forma cristalina e processo para a preparação do mesmo

Country Status (17)

Country Link
US (3) US9238621B2 (pt)
EP (1) EP2723714B1 (pt)
JP (3) JP6212485B2 (pt)
KR (3) KR102277188B1 (pt)
CN (4) CN106349138A (pt)
BR (3) BR122021008918B1 (pt)
CA (3) CA3094762C (pt)
ES (1) ES2636756T3 (pt)
HU (1) HUE033642T2 (pt)
IL (1) IL229647A (pt)
MX (1) MX341839B (pt)
PL (1) PL2723714T3 (pt)
PT (1) PT2723714T (pt)
RU (1) RU2618223C2 (pt)
TW (3) TWI632131B (pt)
WO (1) WO2012164324A1 (pt)
ZA (1) ZA201309357B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231203B1 (hu) 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
CN104884006B (zh) 2012-10-26 2017-12-15 弗赛特影像5股份有限公司 用于持续释放药物到眼睛的眼科系统
US9447014B2 (en) 2012-12-28 2016-09-20 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form, methods for preparation, and methods for use thereof
US9120738B2 (en) * 2012-12-28 2015-09-01 Allergan, Inc. Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
HU231214B1 (hu) * 2014-03-13 2021-11-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás nagytisztaságú prosztaglandinok előállítására
US10273206B2 (en) 2014-06-27 2019-04-30 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof
WO2015199729A1 (en) * 2014-06-27 2015-12-30 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
HU231185B1 (hu) * 2017-07-11 2021-07-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Eljárás Misoprostol előállítására és tisztítására
CN113548993B (zh) * 2021-09-01 2022-05-27 河北化工医药职业技术学院 一种卡前列素的制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954741A (en) * 1972-06-07 1976-05-04 Pfizer Inc. N-substituted prostaglandin carboxamides
US3984424A (en) * 1972-11-08 1976-10-05 Pfizer Inc. P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
HU171155B (hu) * 1973-04-30 1977-11-28 Pfizer Sposob poluchenija oksa-prostaglandinov
HU175889B (en) 1976-04-08 1980-11-28 Chinoin Gyogyszer Es Vegyeszet New process for preparing lactol-alcohol derivatives
HU175217B (hu) * 1977-08-03 1980-06-28 Chinoin Gyogyszer Es Vegyeszet Novyj sposob poluchenija biciklicheskikh laktol-metil-ehfirov
HU178202B (en) 1977-09-26 1982-03-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new,optically active and racemic bicyclic acetals and merkaptals
FR2550799B1 (fr) * 1983-08-17 1986-02-21 Commissariat Energie Atomique Compose marque par une enzyme, son procede de preparation et son utilisation en enzymoimmunologie
JP2721414B2 (ja) * 1988-09-06 1998-03-04 フアーマシア・アンド・アツプジヨン・アー・ベー 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体
SE9002596D0 (sv) * 1990-08-08 1990-08-08 Pharmacia Ab A method for synthesis of prostaglandin derivatives
US5359095A (en) 1990-08-08 1994-10-25 Pharmacia Ab Method for synthesis of prostaglandin derivatives
GB9025509D0 (en) * 1990-11-23 1991-01-09 Fujisawa Pharmaceutical Co New amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
HU212570B (en) * 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
JPH10298446A (ja) * 1997-04-25 1998-11-10 Mitsui Chem Inc 黄色建染染料の製造方法
US7166730B2 (en) * 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
IL143477A (en) * 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
KR100581647B1 (ko) * 2001-07-17 2006-05-22 파마시아 앤드 업존 캄파니 엘엘씨 라타노프로스트 제조를 위한 방법 및 중간체
DE10226942A1 (de) * 2002-06-17 2003-12-24 Symrise Gmbh & Co Kg Verwendung von Mandelsäurealkylamiden als Aromastoffe
US7432287B2 (en) * 2003-02-26 2008-10-07 Banyu Pharmeceutical Co., Ltd. Heteroarylcarbamoylbenzene derivative
GB0329379D0 (en) 2003-12-19 2004-01-21 Johnson Matthey Plc Prostaglandin synthesis
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
IL177762A0 (en) * 2006-08-29 2006-12-31 Arieh Gutman Bimatoprost crystalline form i
AR071312A1 (es) * 2008-04-09 2010-06-09 Scinopharm Taiwan Ltd Proceso para la preparacion de analogos de prostaglandina y sus intermediarios
EP2135860A1 (en) * 2008-06-20 2009-12-23 Sandoz AG Improved process for the production of bimatoprost
GB0819182D0 (en) * 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
EP2349242B1 (en) * 2008-10-29 2018-12-05 Novaer Holdings, Inc. Amino acid salts of prostaglandins
KR101736169B1 (ko) * 2009-03-16 2017-05-16 닛산 가가쿠 고교 가부시키 가이샤 저분자 겔화제로 이루어진 스프레이용 기재
US8519178B2 (en) * 2009-06-22 2013-08-27 Johnson Matthey Public Limited Company Method for the purification of prostaglandins
GB0911000D0 (en) * 2009-06-25 2009-08-12 Givaudan Sa Compounds
WO2011046569A1 (en) * 2009-10-16 2011-04-21 Cayman Chemical Company Process for the preparation of f-series prostaglandins
WO2011050638A1 (zh) 2009-11-02 2011-05-05 上海天伟生物制药有限公司 一种比马前列素晶体及其制备方法和用途
RU2012122367A (ru) 2009-11-05 2013-12-10 Биокон Лимитед Способ получения простагландинов и промежуточные соединения для их получения
MX2012005968A (es) * 2009-11-23 2012-08-15 Allergan Inc 7- [3,5 - dihidroxi - 2 - (3 - hidroxi - 5 - fenil - 1 - enil) - ciclopentil] - n - etil - hept - 5 - enamida (bmato prost) en la forma cristalina ii, metodos de preparacion y metodos para uso del mismo.
EP2495235B1 (en) * 2011-03-04 2015-08-05 Newchem S.p.A. Process for the synthesis of prostaglandins and intermediates thereof
HU231203B1 (hu) * 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására

Also Published As

Publication number Publication date
KR102277188B1 (ko) 2021-07-15
RU2618223C2 (ru) 2017-05-03
EP2723714A1 (en) 2014-04-30
CN106278982B (zh) 2019-06-14
US9238621B2 (en) 2016-01-19
HUE033642T2 (en) 2017-12-28
US20140135503A1 (en) 2014-05-15
TWI632131B (zh) 2018-08-11
CN106349138A (zh) 2017-01-25
JP2017061555A (ja) 2017-03-30
JP2014527026A (ja) 2014-10-09
IL229647A0 (en) 2014-01-30
JP6693859B2 (ja) 2020-05-13
MX2013014034A (es) 2015-06-17
CN106316910A (zh) 2017-01-11
TW201311629A (zh) 2013-03-16
KR20190124804A (ko) 2019-11-05
TW201708191A (zh) 2017-03-01
EP2723714B1 (en) 2017-06-21
KR102038048B1 (ko) 2019-10-30
CN106278982A (zh) 2017-01-04
PL2723714T3 (pl) 2018-02-28
CN103649047A (zh) 2014-03-19
KR20140053941A (ko) 2014-05-08
BR122021008946B1 (pt) 2021-08-10
BR112013030973B1 (pt) 2021-08-10
TWI653222B (zh) 2019-03-11
CA2837261C (en) 2020-12-15
ZA201309357B (en) 2014-08-27
US9573892B2 (en) 2017-02-21
JP6212485B2 (ja) 2017-10-11
WO2012164324A1 (en) 2012-12-06
BR122021008918B1 (pt) 2021-08-10
KR102135550B1 (ko) 2020-07-21
CA3094762A1 (en) 2012-12-06
JP6487410B2 (ja) 2019-03-20
US20160145207A1 (en) 2016-05-26
WO2012164324A9 (en) 2014-01-09
KR20200087871A (ko) 2020-07-21
TW201708190A (zh) 2017-03-01
IL229647A (en) 2017-09-28
PT2723714T (pt) 2017-08-18
US20160137602A1 (en) 2016-05-19
CN103649047B (zh) 2017-01-11
CA3094762C (en) 2023-09-26
MX341839B (es) 2016-09-05
TWI653223B (zh) 2019-03-11
US9856213B2 (en) 2018-01-02
CA2837261A1 (en) 2012-12-06
JP2017075165A (ja) 2017-04-20
ES2636756T3 (es) 2017-10-09
CA3209613A1 (en) 2012-12-06
BR112013030973A8 (pt) 2021-03-30
RU2013158952A (ru) 2015-07-20

Similar Documents

Publication Publication Date Title
BR112013030973A2 (pt) processo para a preparação de amidas de prostaglandina
BR112012028630A2 (pt) dispositivo para comprimir e secar gás
IN2014CN01136A (pt)
BR112014005844A2 (pt) composto orgânico, dispositivo de emisão de luz orgânico, e aparelhos de exibição
DOP2014000197A (es) Composición para el control de plagas que incluye un derivado de iminopiridina novedoso
UA122966C2 (uk) Композиції з покращеним ефектом інгібування уреази, які містять триамід (тіо)фосфорної кислоти і додаткові сполуки, такі як аміни і барвники
BR112012018408A2 (pt) composição do combustível diesel, pacote do aditivo, uso de um aditivo e uso de uma composição do combustível diesel.
ATE477234T1 (de) Synthese von phenolischen estern von hydroxymethylphenolen
AR115561A1 (es) Aditivos para combustible de amonio cuaternario
AR049401A1 (es) Aza-biciclononanos
JP2017521436A5 (pt)
BR112014014148A2 (pt) misturas de ácidos difosfínicos e dialquilfosfínicos, processo para produção das mesmas e uso das mesmas
BR112012032251A2 (pt) processo para a preparação de derivados da 2, 2-difluoroetilamina pela alquilação com 2,2 difluoroetil-1-haloetanos
BR112018073490A2 (pt) 6.7.beta-epóxidos esteroides como intermediários químicos
CY1117087T1 (el) Διαδικασια για την παρασκευη εστερων (5-φθορο-2-μεθυλο-3-κινολιν-2-υλμεθυλ-ινδoλ-1-υλ)- οξικου οξεος
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
AR116423A1 (es) Un proceso de fabricación de compuestos heterocíclicos de 2-nitroimino
AR086451A1 (es) Derivados de 2-amino-3-(imidazol-2-il)piridin-4-ona, preparacion de los mismos y una composicion farmaceutica en base al compuesto
BR112019001015A2 (pt) composto de benzilamida, método para produção do mesmo, e miticida
BR112014000594A2 (pt) composição para o controle de pragas artrópodes e método para controlar pragas artrópodes
BR112015015229A8 (pt) processo para a preparação de um composto da fórmula, e, composto
BR112012020703A2 (pt) composição para o controle de pragas
EA201170057A1 (ru) Способ получения замещенных 2-аминотиазолонов
BR112012029954A2 (pt) composto de poliamida
AR084344A1 (es) Procedimiento para la produccion de esteres alquilicos de bendamustina, bendamustina, y derivados del mismo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/05/2012, OBSERVADAS AS CONDICOES LEGAIS.